



PATENT
Customer No. 22,852
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Schwartz et al.) Group Art Unit: 1648
)
Application No.: 10/083,678) Examiner: PARKIN, J.
)
Filed: February 27, 2002)
)
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION
OF CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING
COMPOSITION *IN VITRO*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated December 29, 2003 (Paper No. 7), the Examiner required restriction under 35 U.S.C. § 121 between: Group I (claims 1, 12, and 16), Group II (claims 1, 12, and 16), Group III (claims 1-4, 12, 16, 17, and 19); Group IV (claims 1-4, 12, 16, 19, and 19); Group V (claims 8-11 and 21-23); Group VI (claim 15); Group VII (claim 15); Group VIII (claim 15); and Group IX (claim 15).

Applicants provisionally elect to prosecute Group I, claims 1, 12, and 16 with traverse. Applicants believe that the restriction requirement is improper because there would not be a serious burden in Examining the groups together. For example, the compositions of claims 2-4 are made using the plasmids of claim 1. Accordingly, applicants respectfully request reconsideration of the requirement.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Moreover, in response to the restriction requirement, applicants submit the following amendments and remarks. Please amend this application as follows.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com